Project description:<p>The main goals of the GICC Study were: 1) to identify novel genetic risk variants for glioma, as well as validate variants implicated by previous genome-wide association studies of glioma; and 2) to explore biologically relevant gene-gene and gene-environment interactions in glioma susceptibility. The GICC Study includes participants from the following centers: Brigham and Women's Hospital (Boston, Massachusetts), Case Western Reserve University (Cleveland, Ohio), Columbia University (New York, New York), the Danish Cancer Society Research Centre (Copenhagen, Denmark), Duke University (Durham, North Carolina), the University of Texas MD Anderson Cancer Center (Houston, Texas), Memorial Sloan Kettering Cancer Center (New York, New York), the Mayo Clinic (Rochester, Minnesota), NorthShore HealthSystem (Chicago, Illinois), Umea University (Umea, Sweden), the University of California, San Francisco (San Francisco, California), the University of Southern California (Los Angeles, California), and the Institute of Cancer Research (London, United Kingdom).</p>

| phs001319 | dbGaP

The MD Anderson Cutaneous Melanoma Case Control Study

Project description:The MD Anderson Cutaneous Melanoma Case Control Study

| PRJNA1076660 | ENA

The MD Anderson Cutaneous Melanoma Case Control Study

Project description:The MD Anderson Cutaneous Melanoma Case Control Study

| PRJNA1076661 | ENA

The MD Anderson Colorectal Cancer Case Control Study

Project description:The MD Anderson Colorectal Cancer Case Control Study

| PRJNA779120 | ENA

The MD Anderson Colorectal Cancer Case Control Study

Project description:The MD Anderson Colorectal Cancer Case Control Study